The United States Food and Drug Administration (FDA) has issued three updates on its activities to combat the novel coronavirus (COVID-19) pandemic: 1) its daily COVID-19 activities update; 2) information on elastomeric respirator innovations to combat COVID-19; and 3) issuance of an Emergency Use Authorization [EUA] for the first molecular non-prescription at-home COVID-19 test. To read the FDA daily update on its activities to combat COVID-19, use the first link below. To read the FDA information on elastomeric respirator innovations to combat COVID-19, use the second link below. To read the FDA announcement and summary of issuing an EUA for the first molecular non-prescription at-home COVID-19 test, use the last link below.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-march-5-2021?utm_medium=email&utm_source=govdelivery (FDA daily COVID-19 update)
https://www.fda.gov/news-events/fda-voices/elastomeric-respirator-innovations-play-critical-role-response-covid-19?utm_medium=email&utm_source=govdelivery (FDA information on elastomeric respirator innovations to combat COVID-19)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-authorization-first-molecular-non-prescription-home-test?utm_medium=email&utm_source=govdelivery (FDA announcement and summary of issuing EUA for first molecular non-prescription at-home COVID-19 test)